SENTIREC-endo研究:低危和中危子宫内膜癌全国采用前哨淋巴结定位的风险与获益
SENTIREC-endo研究为全国多中心前瞻性研究,纳入2017年3月至2022年2月627例低危和中危早期低级别子宫内膜癌患者,评估前哨淋巴结定位的并发症与淋巴水肿风险。前哨淋巴结检出率94.3%,淋巴结转移总体发生率9.3%,超分期识别62%转移灶,术后并发症8%,淋巴水肿改变评分低于临床重要性阈值。
要点
- 前哨淋巴结定位在低危和中危子宫内膜癌中早期淋巴水肿及围手术期和术后并发症风险极低。
- 前哨淋巴结检出率94.3%(591/627),淋巴结转移总体发生率9.3%(58/627)。
- 全国临床实践改变使两个风险组的治疗分配更准确,支持该技术在早期低级别子宫内膜癌中进一步国际推广。
核心结论
- 在低危和中危子宫内膜癌女性中,前哨淋巴结定位携带极低的早期淋巴水肿及围手术期和术后并发症风险。
- 全国临床实践的改变使两个风险组的治疗分配更准确,从而支持前哨淋巴结技术在早期低级别子宫内膜癌中的进一步国际实施。
研究设计与样本
- 全国多中心前瞻性研究,纳入2017年3月至2022年2月低危和中危子宫内膜癌女性,评估前哨淋巴结定位。
- 共627例女性纳入分析,其中低危458例,中危169例。
- 术后并发症按Clavien-Dindo分级,淋巴水肿通过基线及术后三个月经验证的患者报告结局指标评估肿胀和沉重感的发生率及变化评分。
主要发现
- 前哨淋巴结检出率为94.3%(591/627)。
- 淋巴结转移总体发生率为9.3%(58/627);低危组为4.4%(20/458),中危组为22.5%(38/169)。
- 超分期识别了62%(36/58)的转移灶。
- 术后并发症发生率为8%(50/627),仅0.3%(2/627)发生与前哨淋巴结操作相关的术中并发症。
- 淋巴水肿变化评分为4.5/100,置信区间(2.9-6.0),低于临床重要性阈值;肿胀和沉重感发生率分别为5.2%和5.8%。
临床怎么用
- 原文结论指出,前哨淋巴结定位在低危和中危子宫内膜癌中早期淋巴水肿及围手术期和术后并发症风险极低。
- 原文结论指出,全国临床实践的改变使两个风险组的治疗分配更准确,并支持前哨淋巴结技术在早期低级别子宫内膜癌中的进一步国际实施。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The SENTIREC-endo study aims to investigate risks and benefits of a national protocolled adoption of sentinel lymph node (SLN) mapping in women with early-stage low-grade endometrial cancer (EC) with low- (LR) and intermediate-risk (IR) of lymph node metastases. METHODS: We performed a national multicenter prospective study of SLN-mapping in women with LR and IR EC from March 2017-February 2022. Postoperative complications were classified according to Clavien-Dindo. Lymphedema was assessed as a change score and as incidence of swelling and heaviness evaluated by validated patient-reported outcome measures at baseline and three months postoperatively. RESULTS: 627 women were included in the analyses; 458 with LR- and 169 with IR EC. The SLN detection rate was 94.3% (591/627). The overall incidence of lymph node metastases was 9.3% (58/627); 4.4% (20/458) in the LR- and 22.5% (38/169) in the IR group. Ultrastaging identified 62% (36/58) of metastases. The incidence of postoperative complications was 8% (50/627) but only 0.3% (2/627) experienced an intraoperative complication associated with the SLN procedure. The lymphedema change score was below the threshold for clinical importance 4.5/100 CI: (2.9-6.0), and the incidence of swelling and heaviness was low; 5.2% and 5.8%, respectively. CONCLUSION: SLN mapping in women with LR and IR EC carries a very low risk of early lymphedema and peri- and postoperative complications. The national change in clinical practice contributed to a more correct treatment allocation for both risk groups and thus supports further international implementation of the SLN technique in early stage, low grade EC.
引用
- Bjørnholt SM, Sponholtz SE, Mogensen O, et al. The SENTIREC-endo study - Risks and benefits of a national adoption of sentinel node mapping in low and intermediate risk endometrial cancer. Gynecol Oncol. 2023. PMID: 36893488. doi:10.1016/j.ygyno.2023.02.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。